Market Overview

Synexus Announces U.S.-Based Registry to Power Major Longitudinal Study on Brain Aging

Share:

Synexus HealthyMinds Registry will support some of the largest
studies ever undertaken to identify ways to prevent Alzheimer's disease
and other forms of dementia

Synexus, the leading global network of dedicated research sites, today
announced a collaboration with the University
of Exeter
in the United Kingdom to launch one of the largest,
registry-based research initiatives in the United States to help
understand how healthy brains age.

The initial goal of the Synexus HealthyMinds Registry (Synexus HMR) is
to register 30,000 adults age 50 or older without signs of dementia for
a five-year study to examine the lifestyle and genetic risk factors
impacting cognitive function over time to identify potential methods of
prevention and possible treatments.

Synexus
is collaborating with Acurian,
a leading full-service provider of global patient enrollment and
retention solutions, to help enroll study participants. Synexus and
Acurian are part of Accelerated Enrollment Solutions (AES), a business
unit of Pharmaceutical Product Development, LLC (PPD),
the global contract research organization. Drawing on its extensive
recruitment expertise and a database of over 100 million U.S.
households, Acurian provides one of the largest pools of potential
participants for Alzheimer's disease longitudinal screening.

"Synexus HMR offers participants the opportunity to help society, and
potentially themselves and their loved ones, better understand what
causes cognitive decline," said Dawie Wessels, chief medical officer of
Synexus. "We hope to identify ways to prevent and treat dementia so
people can maintain greater independence as they age. The registry
provides a high level of engagement, pushing out relevant information
about the latest advancements in dementia research and treatments, as
well as brain-training games designed to help participants stay sharp."

The first Synexus HMR study is being conducted exclusively online,
meaning people with access to the internet can participate in cognitive
assessments, lifestyle and medical questionnaires, and brain-training
exercises without leaving their homes. In addition, participants will be
among the first to learn about clinical trials of promising new
treatments for Alzheimer's and other forms of dementia. Additional
information about Synexus HMR and how to participate at no cost is
available at www.SynexusHMR.com.

"We know dementia risk can be reduced by one-third through improving
lifestyle factors from midlife," said Professor Clive Ballard, executive
dean and pro-vice-chancellor of the University of Exeter Medical School.
"Our study in the United States will provide valuable information about
how the brain changes with age, which combination of factors such as
exercise and diet really work, and how we can best encourage people to
adopt these changes. This is already proving successful in the U.K.,
where more than 25,000 people have signed up to help develop better
approaches to prevention and treatment, and we're delighted to help
bring this opportunity to the U.S."

About Accelerated Enrollment Solutions

Accelerated Enrollment Solutions is a business unit of PPD that offers
both sponsors and contract research organizations best-in-class site and
enrollment solutions, with tiered offerings combining the expertise, as
needed, of industry leaders PPD, Synexus, Acurian and Optimal Research.
These solutions are available as discrete services or integrated to
provide a cohesive and highly differentiated trial acceleration strategy
for insourced or outsourced clinical studies, all under
performance-based commercial terms. Acurian and Synexus have proven
track records for enrolling patients and study conduct through
proprietary, direct-to-patient recruitment methodologies and a global
site network. When combined, these services provide a new standard of
clinical trial productivity that delivers more patients from fewer sites
in less time.

About the University of Exeter Medical School

The University of Exeter Medical School is improving the health and
well-being of the South West United Kingdom and beyond through the
development of high-quality graduates and world-leading research that
has international impact. As part of a Russell Group university, the
medical school combines this world-class research with very high levels
of student satisfaction. The institution achieves its mission through
swiftly turning new discoveries into treatments therapies, and through
nurturing graduates, staff and researchers who are critical thinkers and
problem solvers. The University of Exeter Medical School works closely
with the National Health Service and health care providers to ensure its
innovations tackle complex global health care needs. For more
information, visit https://medicine.exeter.ac.uk.

About PPD

PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and lifecycle
management services. Our clients and partners include pharmaceutical,
biotechnology, medical device, academic and government organizations.
With offices in 47 countries and approximately 20,000 professionals
worldwide, PPD applies innovative technologies, therapeutic expertise
and a firm commitment to quality to help clients and partners bend the
cost and time curve of drug development and optimize value in delivering
life-changing therapies to improve health. For more information, visit www.ppdi.com.

View Comments and Join the Discussion!